Ashorn P, McQuade T J, Thaisrivongs S, Tomasselli A G, Tarpley W G, Moss B
Laboratory of Viral Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892.
Proc Natl Acad Sci U S A. 1990 Oct;87(19):7472-6. doi: 10.1073/pnas.87.19.7472.
The activity of the human immunodeficiency virus (HIV) protease is essential for processing of the gag-pol precursor proteins and maturation of infectious virions. We have prepared a peptidomimetic inhibitor, U-75875, that inhibited HIV-1 gag-pol protein processing in an essentially irreversible manner. Noninfectious virus particles produced in the presence of the drug contained gag precursors and were morphologically immature. In human peripheral blood mononuclear cells and in a continuous cell line, U-75875 completely blocked HIV replication; in the latter case, no spread occurred over a period of 4 weeks. U-75875, on a molar basis, was as potent as 3'-azido-3'-deoxythymidine in blocking HIV-1 replication in human lymphocytes and also inhibited HIV-2 and simian immunodeficiency virus proteases, demonstrating that it has broad activity. These results provide further evidence for the therapeutic potential of protease inhibitors in HIV infection.
人类免疫缺陷病毒(HIV)蛋白酶的活性对于gag-pol前体蛋白的加工以及传染性病毒粒子的成熟至关重要。我们制备了一种拟肽抑制剂U-75875,它以基本上不可逆的方式抑制HIV-1 gag-pol蛋白的加工。在药物存在下产生的无感染性病毒颗粒含有gag前体,并且在形态上是不成熟的。在人外周血单核细胞和连续细胞系中,U-75875完全阻断了HIV复制;在后一种情况下,在4周的时间内没有发生病毒传播。在摩尔基础上,U-75875在阻断HIV-1在人淋巴细胞中的复制方面与3'-叠氮基-3'-脱氧胸苷一样有效,并且还抑制HIV-2和猿猴免疫缺陷病毒蛋白酶,表明它具有广泛的活性。这些结果为蛋白酶抑制剂在HIV感染中的治疗潜力提供了进一步的证据。